OICR enters collaboration with Janssen Inc. in the development of multi-centre clinical trials to identify improved prostate

OICR enters collaboration with Janssen Inc. in the development of multi-centre 
clinical trials to identify improved prostate cancer biomarkers 
TORONTO, April 22, 2013 /CNW/ - Dr. Tom Hudson, President and Scientific 
Director of the Ontario Institute for Cancer Research (OICR) today announced a 
collaboration with Janssen Inc. to find and test new biomarkers to identify 
patients with hormone resistant prostate cancer at high risk for disease 
progression and biomarkers of response to therapy. These biomarkers could lead 
to more personalized treatments and fewer side effects for prostate cancer 
"This collaboration will further advance the world-class research in prostate 
cancer already underway in Ontario," said Dr. Hudson. "We are happy to partner 
with Janssen on this project in the hope of providing patients diagnosed with 
prostate cancer better and more precise treatment options." 
"Today's announcement will see some of Ontario's most talented researchers 
working together to improve the lives of patients diagnosed with prostate 
cancer," said Reza Moridi, Ontario Minister of Research and Innovation. "Our 
government is working to make Ontario a place where this type of innovative 
partnership can flourish - both advancing knowledge and helping to strengthen 
our economy." 
The project will be led by OICR's High Impact Clinical Trials Program in 
collaboration with researchers in Toronto, Hamilton, London and Ottawa. OICR 
and its research partners will leverage the province's expertise in genomics, 
circulating tumour cells and molecular imaging to establish up to three 
multi-centre clinical trials in Ontario. The trials could last for up to three 
"With improved biomarkers doctors can better differentiate those patients with 
aggressive prostate cancer from those with non-aggressive prostate cancer and 
those patients that are responding to treatments from those that are not," 
said Dr. Janet Dancey, Director of OICR's High Impact Clinical Trials Program. 
"This means we could better tailor therapy to the individual patient and 
potentially spare many men from the serious side effects associated with 
prostate cancer treatment, while also finding improved ways to treat men with 
more aggressive disease." 
Specific objectives of the project include evaluating the similarity between 
archived diagnostic samples, serial samples of circulating tumour cells and 
recent tumour biopsies, using next generation sequencing to correlate 
molecular profiles with outcomes in patients with hormone resistant prostate 
cancer and evaluating new imaging probes to assess tumour burden in patients 
and better determine response to treatment. 
Prostate cancer is the most common cancer among Canadian men, excluding 
non-melanoma skin cancer. An estimated 26,500 men are diagnosed with prostate 
cancer and 4,000 will die of the disease each year. Hormone resistant prostate 
cancer refers to prostate cancer that has become resistant to hormone therapy. 
This usually occurs within one to three years after the start of treatment. 
Finding new biomarkers will allow doctors to determine which patients with 
hormone resistant prostate cancer are at risk of rapid progression and which 
are not, allowing doctors to better tailor treatments to individual patients 
and monitor their progression more precisely. 
The Ontario Institute for Cancer Research 
OICR is an innovative cancer research and development institute dedicated to 
prevention, early detection, diagnosis and treatment of cancer. The Institute 
is an independent, not-for-profit corporation, supported by the Government of 
Ontario. The annual budget for OICR, its research partners and collaborators 
exceeds $150 million. This supports more than 1,600 investigators, clinician 
scientists, research staff and trainees located at its headquarters and in 
research institutes and academia across the Province of Ontario. OICR has key 
research efforts underway in small molecules, biologics, stem cells, imaging, 
genomics, informatics and bio-computing. For more information, please visit 
the website atwww.oicr.on.ca 
Contact: Hal Costie Senior Communications Officer 
Email:hal.costie@oicr.on.ca Telephone: 647-260-7921 Mobile: 647-963-5289 
SOURCE: Ontario Institute for Cancer Research 
To view this news release in HTML formatting, please use the following URL: 
CO: Ontario Institute for Cancer Research
ST: Ontario
-0- Apr/22/2013 14:00 GMT
Press spacebar to pause and continue. Press esc to stop.